132 related articles for article (PubMed ID: 33793964)
1. Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors.
Sasaki K; Kantarjian HM; Short NJ; Samra B; Khoury JD; Kanagal Shamanna R; Konopleva M; Jain N; DiNardo CD; Khouri R; Garcia-Manero G; Kadia TM; Wierda WG; Khouri IF; Kebriaei P; Mehta RS; Champlin RE; Garris R; Cheung CM; Daver N; Thompson PA; Yilmaz M; Ravandi F; Jabbour E
Cancer; 2021 Aug; 127(15):2648-2656. PubMed ID: 33793964
[TBL] [Abstract][Full Text] [Related]
2. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis.
Sasaki K; Jabbour EJ; Ravandi F; Short NJ; Thomas DA; Garcia-Manero G; Daver NG; Kadia TM; Konopleva MY; Jain N; Issa GC; Jeanis V; Moore HG; Garris RS; Pemmaraju N; Cortes JE; O'Brien SM; Kantarjian HM
Cancer; 2016 Dec; 122(23):3650-3656. PubMed ID: 27479888
[TBL] [Abstract][Full Text] [Related]
3. Ponatinib vs. Imatinib as Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Matching Adjusted Indirect Comparison.
Ribera JM; Prawitz T; Freitag A; Sharma A; Dobi B; Rizzo F; Sabatelli L; Patos P
Adv Ther; 2023 Jul; 40(7):3087-3103. PubMed ID: 37208556
[TBL] [Abstract][Full Text] [Related]
4. Ponatinib Improved the Prognosis of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Japanese Single-Center Cohort Study.
Tozawa N; Yamashita T; Nara M; Fujioka Y; Ikeda S; Kobayashi T; Kobayashi I; Kitadate A; Kameoka Y; Takahashi N
Cureus; 2023 Dec; 15(12):e50416. PubMed ID: 38222242
[TBL] [Abstract][Full Text] [Related]
5. Management of Philadelphia chromosome positive acute lymphoblastic leukemia in the current era.
Badar T; Alkhateeb H; Aljurf M; Kharfan-Dabaja MA
Curr Res Transl Med; 2023; 71(2):103392. PubMed ID: 37121211
[TBL] [Abstract][Full Text] [Related]
6. SOHO State of the Art Updates and Next Questions | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in Adults: Therapeutic Options and Challenges in 2023.
Rahman ZA; Kebriaei P
Clin Lymphoma Myeloma Leuk; 2023 Nov; 23(11):779-785. PubMed ID: 37438208
[TBL] [Abstract][Full Text] [Related]
7. Is intensive chemotherapy and allogeneic stem cell transplantation mandatory for curing Philadelphia chromosome-positive acute lymphoblastic leukemia in young patients in the era of multitarget agents?
Sohn SK; Lee JM; Jang Y; Lee Y; Na J; Cho HJ; Moon JH; Baek DW
Expert Rev Hematol; 2024 May; ():1-7. PubMed ID: 38755522
[TBL] [Abstract][Full Text] [Related]
8. Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Othman T; Koller P; Tsai NC; Yang D; Pourhassan H; Agrawal V; Ngo D; Chen J; Farol L; Spielberger R; Sahebi F; Al Malki MM; Cai JL; Sandhu KS; Mansour J; Salhotra A; Ali H; Aribi A; Arslan S; Marcucci G; Forman SJ; Stein AS; Nakamura R; Pullarkat V; Aldoss I; Mei M
Am J Hematol; 2024 May; ():. PubMed ID: 38804599
[TBL] [Abstract][Full Text] [Related]
9. Case report: Olverembatinib monotherapy: the chemotherapy-free regimen for an elderly patient with relapsed Ph-positive acute lymphoblastic leukemia.
Ding J; Li W
Front Pharmacol; 2023; 14():1320641. PubMed ID: 38035030
[No Abstract] [Full Text] [Related]
10. Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Children: A Retrospective Cohort Study at a Pediatric Oncology Center.
Maia Moço L; Fraga A; Maia I; Almeida M
Cureus; 2024 Feb; 16(2):e54154. PubMed ID: 38496108
[TBL] [Abstract][Full Text] [Related]
11. Real-world outcomes of ponatinib treatment in 724 patients with CML and Ph+ ALL: a post-marketing surveillance study with a special interest in arterial occlusive events in Japan.
Takahashi N; Kondo T; Ikari Y; Fukumoto Y; Hatake K; Masunari A; Nishibayashi S; Kageyama A; Fukuta Y; Tojo A
Jpn J Clin Oncol; 2024 May; ():. PubMed ID: 38747937
[TBL] [Abstract][Full Text] [Related]
12. Asciminib stands out as the superior tyrosine kinase inhibitor to combine with anti-CD20 monoclonal antibodies for the treatment of CD20+ Philadelphia-positive B-cell precursor acute lymphoblastic leukemia in preclinical models.
Domka K; Dąbkowska A; Janowska M; Urbańska Z; Pastorczak A; Winiarska M; Fidyt K; Lachota M; Patkowska E; Sędek Ł; Perkowski B; Hunia J; Jakubowska J; Krzymieniewska B; Lech-Marańda E; Młynarski W; Szczepański T; Firczuk M
Haematologica; 2024 Jun; ():. PubMed ID: 38841802
[TBL] [Abstract][Full Text] [Related]
13. Low-Intensity and Chemo-Free Treatments in Ph+ ALL: Progression-Free Survival Based on Indirect Comparisons.
Rivano M; Mengato D; Chiumente M; Messori A
Hematol Rep; 2023 Nov; 15(4):670-683. PubMed ID: 38132276
[TBL] [Abstract][Full Text] [Related]
14. Ponatinib-Induced Pneumonitis with Severe Acute Respiratory Distress Syndrome.
Ferreira SD; Jardim M; Câmara M; Jacinto F; Aveiro F; Nóbrega JJ
Eur J Case Rep Intern Med; 2023; 10(12):004162. PubMed ID: 38077703
[TBL] [Abstract][Full Text] [Related]
15. A comprehensive case study on successful multimodal therapy in philadelphia chromosome-positive acute myeloid leukemia with
Haider SMW; Zehra M; Shah NN; Sotomayor EM; Swoboda DM
Leuk Res Rep; 2024; 21():100461. PubMed ID: 38736691
[TBL] [Abstract][Full Text] [Related]
16. Outcomes following allogeneic hematopoietic cell transplantation relapse in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Othman T; Li S; Zhang J; Pourhassan H; Agrawal V; Ngo D; Chen J; Farol L; Sahebi F; Sandhu K; Spielberger R; Marcucci G; Forman SJ; Stein AS; Nakamura R; Pullarkat V; Mei M; Aldoss I; Koller P
Am J Hematol; 2024 May; ():. PubMed ID: 38800943
[TBL] [Abstract][Full Text] [Related]
17. Integrated systems biology analysis of acute lymphoblastic leukemia: unveiling molecular signatures and drug repurposing opportunities.
Budak B; Tükel EY; Turanlı B; Kiraz Y
Ann Hematol; 2024 Jun; ():. PubMed ID: 38836918
[TBL] [Abstract][Full Text] [Related]
18. Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing therapy.
Short NJ; Jabbour E; Nasr LF; Jain N; Haddad FG; Issa GC; Sasaki K; Senapati J; Kebriaei P; Garris R; Konopleva M; Ravandi F; Kantarjian H
Am J Hematol; 2024 Apr; ():. PubMed ID: 38607091
[No Abstract] [Full Text] [Related]
19. Phase 2 trial of induction with dasatinib and consolidation with hyper-CVAD plus dasatinib followed by allografting for Ph-positive acute lymphoblastic leukemia in adults.
Oh I; Hatano K; Ikeda T; Toda Y; Minakata D; Kawaguchi S; Morita K; Yamamoto C; Ashizawa M; Sato K; Kameda K; Gomyo A; Misaki Y; Kawamura S; Kimura S; Kobayashi H; Sato H; Nakasone H; Ohmine K; Fujiwara S; Kako S; Kanda Y
Leuk Res; 2024 Feb; 137():107438. PubMed ID: 38278044
[No Abstract] [Full Text] [Related]
20. Dasatinib-induced hypoglycemia in a patient with acute lymphoblastic leukemia.
Lundholm MD; Charnogursky GA
Clin Case Rep; 2020 Jul; 8(7):1238-1240. PubMed ID: 32695366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
